Journal article · 2026 · Open access

Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery

Yidi Jiang, Shuangmei Li, Elisa Anamaria Liehn, Chee Seng Chan, Ji Xin Tan, Tian Xin Phua, Shing Leng Chan, Choon Keong Lee, Xiangliang Lin, Natalie Jun Hui Soh, Gabriele Grassi, Jiong-Wei Wang and 6 more

Journal of Controlled Release, 400(Pt A), 115504 · Published 3 November 2026 · DOI 10.1016/j.jconrel.2026.115504

Open PDFView at the publisherCite this paper

In brief

“Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery” is a 2026 journal article by Yidi Jiang and 17 co-authors, published in Journal of Controlled Release. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Journal of Controlled Release.

Citations
0
References
144
Authors
18

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease characterized by steatosis, inflammation, and progressive fibrosis. Increasing evidence suggests that cellular senescence contributes to MASH progression by promoting lipid accumulation, inflammatory signaling, and fibrogenic responses, highlighting hepatic senescent cells as a potential therapeutic target. Senolytics selectively eliminate senescent cells, but their application in MASH remains insufficiently explored. In this study, we developed in vitro models integrating hepatic lipid accumulation and hepatocyte-macrophage inflammatory crosstalk to facilitate investigation of the contribution of cellular senescence to MASH pathology and to evaluate senescence-targeted interventions. Senescent hepatic cells showed enhanced lipid accumulation and amplified inflammatory signaling with macrophages. Natural Extracellular Vesicles (EVs) derived from adipocytes reduced senescence-associated phenotypes but exhibited context-dependent biological effects, highlighting the limited control over their intrinsic bioactivity. Navitoclax, a senolytic targeting anti-apoptotic BCL-2 family proteins, reduced senescence-associated phenotypes, but its clinical use is limited by its dose-dependent toxicity. Hence, we conceived nano-Cell Vesicle Technology Systems (nCVTs), a biohybrid-based platform combining cell-derived membranes with synthetic lipids for controlled delivery of navitoclax. Navitoclax-loaded nCVTs retained senolytic activity and reduced inflammatory signaling and fibrotic activation in vitro. Importantly, in a Western diet- and fructose-induced (WDF) MASH mouse model, navitoclax-loaded AML-12-derived nCVTs alleviated hepatic lipid accumulation while reducing histopathological activity score and fibrotic profiles. Neither navitoclax formulation reduced platelet counts or hemoglobin concentrations at the tested dose. Collectively, these findings support cellular senescence as a therapeutically relevant target for MASH and identify nCVTs as a promising engineered platform for controlled senolytic delivery.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Jiang, Y., Li, S., Liehn, E. A., Chan, C. S., Tan, J. X., Phua, T. X., Chan, S. L., Lee, C. K., Lin, X., Soh, N. J. H., Grassi, G., Wang, J.-W., Wang, T., Singh, B. K., Tripathi, M., Toh, W. S., Yu, V. C. K., & Pastorin, G. (2026). Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery. Journal of Controlled Release, 400(Pt A), 115504. https://doi.org/10.1016/j.jconrel.2026.115504

MLA 9

Jiang, Yidi, et al. “Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery.” Journal of Controlled Release, vol. 400, no. Pt A, 2026, p. 115504. https://doi.org/10.1016/j.jconrel.2026.115504.

Chicago

Jiang, Yidi, Shuangmei Li, Elisa Anamaria Liehn, Chee Seng Chan, Ji Xin Tan, Tian Xin Phua, Shing Leng Chan, et al. 2026. “Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery.” Journal of Controlled Release 400 (Pt A): 115504. https://doi.org/10.1016/j.jconrel.2026.115504.

Harvard

Jiang, Y. et al. (2026) ‘Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery’, Journal of Controlled Release, 400(Pt A), p. 115504. doi:10.1016/j.jconrel.2026.115504.

IEEE

Y. Jiang et al., “Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery,” Journal of Controlled Release, vol. 400, no. Pt A, p. 115504, 2026, doi: 10.1016/j.jconrel.2026.115504.

BibTeX

@article{jiang2026validation,
  title     = {{Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery}},
  author    = {Jiang, Yidi and Li, Shuangmei and Liehn, Elisa Anamaria and Chan, Chee Seng and Tan, Ji Xin and Phua, Tian Xin and Chan, Shing Leng and Lee, Choon Keong and Lin, Xiangliang and Soh, Natalie Jun Hui and Grassi, Gabriele and Wang, Jiong-Wei and Wang, Tong and Singh, Brijesh Kumar and Tripathi, Madhulika and Toh, Wei Seong and Yu, Victor Chun Kong and Pastorin, Giorgia},
  journal   = {Journal of Controlled Release},
  year      = {2026},
  volume    = {400},
  number    = {Pt A},
  pages     = {115504},
  doi       = {10.1016/j.jconrel.2026.115504},
  url       = {https://doi.org/10.1016/j.jconrel.2026.115504}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment

  • nonalcoholic steatohepatitis
  • cellular senescence
  • senolytics
  • navitoclax
  • extracellular vesicles
  • hepatic lipid accumulation
  • liver fibrosis
  • controlled drug delivery

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Jiang, Y., Li, S., Liehn, E. A., Chan, C. S., Tan, J. X., Phua, T. X., Chan, S. L., Lee, C. K., Lin, X., Soh, N. J. H., Grassi, G., Wang, J.-W., Wang, T., Singh, B. K., Tripathi, M., Toh, W. S., Yu, V. C. K., & Pastorin, G. (2026). Validation of senescence as a therapeutic target in metabolic dysfunction–associated steatohepatitis (MASH) through navitoclax delivery. Journal of Controlled Release, 400(Pt A), 115504. https://doi.org/10.1016/j.jconrel.2026.115504

How many times has this paper been cited?

0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Controlled Release: sign in and open the PDF from this page.

Who wrote this paper?

Yidi Jiang, Shuangmei Li, Elisa Anamaria Liehn, Chee Seng Chan, Ji Xin Tan, Tian Xin Phua, Shing Leng Chan, Choon Keong Lee, Xiangliang Lin, Natalie Jun Hui Soh, Gabriele Grassi, Jiong-Wei Wang and 6 more.

What is the DOI of this paper?

10.1016/j.jconrel.2026.115504, permanently at https://doi.org/10.1016/j.jconrel.2026.115504. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.